Tag: Ppar agonist

In June 2024, Iqirvo (elafibranor) received accelerated approval from the FDA, offering a new treatment option for adults with primary biliary cholangitis (PBC). For those searching for information, it is important to note that the medication is spelled 'Iqirvo,' and this guide answers the question of what does Icarvo treat by detailing the correct medication.

Animal studies have shown that fenofibrate significantly decreases visceral adipose tissue mass and reduces the size of abdominal fat cells. However, the question, **Does fenofibrate reduce visceral fat?**, has a more complex answer in human medicine, where the drug is primarily prescribed for lipid management rather than weight loss.

While some animal studies using high doses of fenofibrate showed an increased incidence of liver and pancreatic carcinomas, a meta-analysis of 17 human randomized controlled trials (RCTs) involving 44,929 participants found that fibrate therapy had a neutral effect on cancer incidence and mortality [1.3.5, 1.5.6]. The question of 'Is fenofibrate carcinogenic?' remains complex, with significant differences between rodent and human responses.